Longitudinal analysis of long and short term-survivors with glioblastoma after interstitial photodynamic therapy
Foglar, M. 1; Aumiller, M. 1,2; Bochmann, K. 4; Buchner, A. 2; El Fahim, M. 1 Forbrig, R. 4; Quach, S. 3; Sroka, R. 1,2; Stepp, H. 1,2; Thon, N. 3 and Rühm, A. 1,2
1 Laser-Forschungslabor, LIFE Center, University Hospital, LMU Munich, Munich, Germany
2 Department of Urology, University Hospital of Munich LMU, Munich, Germany
3 Department of Neurosurgery, University Hospital of Munich LMU, Munich, Germany
4 Department of Neuroradiology, University Hospital of Munich LMU, Munich, Germany
Abstract
Glioblastoma, representing the most frequent malignant brain tumour inheriting a poor survival, poses an extraordinary challenge in modern medicine. Among the multitude of new approaches, interstitial photodynamic therapy (iPDT) offers promising results. This technique takes effect by devitalizing the tumour tissue by tumour-selective uptake of a photosensitizing drug. To activate the sensitizer, stereotactically implanted optical fibres illuminate the region of interest. Due to these peculiarities, post-treatment image analysis is challenging. In this study, we analysed iPDT-induced changes using dedicated MRI sequences including diffusion-weighted as well as T2-weighted and contrast-enhanced T1-weighted imaging both directly after iPDT and during follow-up. Directly after iPDT, MRI showed a diffusion-restriction at the tumour-margin and a reduced/vanished contrast-enhancement. Regarding follow-up MRI, signs of tumour relapse were noted. Regarding molecular genetics, we found an association between improved survival and the prognostically important MGMT promoter. In conclusion, iPDT represents a promising treatment in glioblastoma patients.
Speaker
Marco Foglar
Laser Research Laboratory / LMU Munich
Germany
Discussion
Ask question
